|Table of Contents|

Efficacy of different follow up treatment regimens and prognostic factors of trastuzumab failure in HER-2 positive breast cancer patients

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2021 01
Page:
61-65
Research Field:
Publishing date:

Info

Title:
Efficacy of different follow up treatment regimens and prognostic factors of trastuzumab failure in HER-2 positive breast cancer patients
Author(s):
ZHANG Jinru; QI Tao; LIU Haiming; NING Peng
Oncology Department，Baoji High-tech People's Hospital，Shaanxi Baoji 721013，China.
Keywords:
HER-2 positive; breast cancer; trastuzumab; prognostic factors
PACS:
R737.9
DOI:
10.3969/j.issn.1672-4992.2021.01.013
Abstract:
Objective：To study the effect of different follow-up treatment regimens after trastuzumab treatment failure in HER-2 positive breast cancer patients and analyze the prognostic factors.Methods：94 patients with HER-2 positive advanced breast cancer who had failed trastuzumab treatment from January 2014 to December 2016 were analyzed retrospectively.According to their different follow-up treatment regimens，they were divided into group A，group B and group C，respectively，who received simple chemotherapy，trastuzumab+chemotherapy，and lapatinib+chemotherapy.The therapeutic effects of three groups were compared，and the clinical factors that may affect the therapeutic effect of anti HER-2 were analyzed.Results：94 patients were followed up.The median follow-up time was 22.3 months.There were significant differences in PFS among the three groups(P<0.000 1).The mPFS in three groups were 3 months，4.5 months and 6 months.Compared with group A and group B，the PFS of group C was significantly prolonged.Compared with group A，the PFS of group B was significantly prolonged.The ORR of group A，B and C were 8.7%，29.7% and 38.2%，and the CBR of group A，B and C were 21.7%，54.1% and 64.7%.The above differences were statistically significant(P<0.05).The analysis of clinical factors that may affect PFS showed that lapatinib，first-line treatment(trastuzumab) with a benefit time of ≥6 months and no visceral metastasis were the influencing factors of PFS，while lapatinib and first-line treatment(trastuzumab) with a benefit time of ≥6 months were the independent influencing factors of PFS.Conclusion：For the patients with HER-2 positive advanced breast cancer who failed trastuzumab treatment，the follow-up treatment with targeted drugs of anti HER-2 can improve the prognosis of the patients.

References:

[1]SIEGEL RL，MILLER KD，JEMAL A.Cancer statistics，2019［J］.CA Cancer J Clin，2019，69(1)：7-34.
[2]BRAY F，FERLAY J，SOERJOMATARAM I，et al.Global cancer statistics 2018：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin，2018，68(6)：394-424.
[3]JANITZ A，WENDELBOE AM，CHOU AF，et al.Impact of a national cancer prevention and treatment program on the prevalence of late-stage breast cancer diagnoses in oklahoma［J］.J Okla State Med Assoc，2016，109(7-8)：366-373.
[4]LEINERT E，SINGER S，JANNI W，et al.The impact of age on quality of life in breast cancer patients receiving adjuvant chemotherapy：A comparative analysis from the prospective multicenter randomized ADEBAR trial［J］.Clin Breast Cancer，2017，17(2)：100-106.
[5]赵美琳，李卓琳，丁莹莹.乳腺癌异质性的影像学研究现状［J］.放射学实践，2018，33(02)：215-218. ZHAO ML，LI ZL，DING YY.Imaging research status of heterogeneity in breast cancer［J］.Radiology Practice，2018，33(02)：215-218.
[6]HOSSEINI H，OBRADOVIC MMS，HOFFMANN M，et al.Early dissemination seeds metastasis in breast cancer［J］.Nature，2016，540(7634)：552-558.
[7]张海峰，张海林，张浩，等.乳腺癌患者癌组织中人表皮生长因子受体2的表达及与预后关系的分析［J］.中国综合临床，2017，33(11)：961-964. ZHANG HG，ZHANG HL，ZHANG H，et al.Analysis of human epidermal growth factor receptor 2 expression in cancer tissues of breast cancer patients and its relationship with prognosis［J］.Chinese Journal of Integrative Clinical，2017，33(11)：961-964.
[8]罗蒙，许春景，孙雨婷，等.HER2阳性乳腺癌的靶向治疗及其耐药机制［J］.实用肿瘤杂志，2018，33(3)：283-288. LUO M，XU CJ，SUN YT，et al.Targeted therapy and drug resistance mechanism of HER2 positive breast cancer［J］.Journal of Applied Oncology，2018，33(3)：283-288.
[9]严颖，李惠平，邸立军，等.曲妥珠单抗治疗后进展的转移性乳腺癌继续曲妥珠单抗治疗的疗效及安全性分析［J］.癌症进展，2016，14(12)：1191-1194，1198. YAN Y，LI HP，DI LJ，et al.Efficacy and safety analysis of continuous trastuzumab treatment for metastatic breast cancer after trastuzumab treatment［J］.Cancer Progress，2016，14(12)：1191-1194，1198.
[10]韩逸群，樊英，陈闪闪，等.跨线曲妥珠单抗治疗HER2阳性乳腺癌疗效分析［J］.临床药物治疗杂志，2019，17(6)：71-75. HAN YQ，FAN Y，CHEN SS，et al.Efficacy of trans-linear trastuzumab in the treatment of HER2 positive breast cancer［J］.Journal of Clinical Pharmacotherapy，2019，17(6)：71-75.
[11]于晓杰.新型抗HER2单克隆抗体的抗肿瘤作用及机制研究［D］.上海：第二军医大学，2017. YU XJ.Anti-tumor effect and mechanism of novel anti-HER2 monoclonal antibody［D］.Shanghai:Second Military Medical University，2017.
[12]汪云超，李艳萍.人表皮生长因子受体-2阳性乳腺癌靶向治疗新进展［J］.中华内分泌外科杂志，2015，9(5)：428-431. WANG YC，LI YP.Advances in targeted therapy of human epidermal growth factor receptor-2 positive breast cancer［J］.Chinese Journal of Endocrinology and Surgery，2015，9(5)：428-431.
[13]黄玉琴.注射用曲妥珠单抗对人表皮生长因子受体2阳性晚期乳腺癌化疗患者血清肿瘤标志物及免疫功能的影响［J］.中国综合临床，2017，33(8)：748-752. HUANG YQ.Effects of trastuzumab for injection on serum tumor markers and immune function in patients undergoing chemotherapy for advanced breast cancer with positive epidermal growth factor receptor 2［J］.Chin J Clin Sinica，2017，33(8)：748-752.
[14]TOLANEY SM，BARRY WT，DANG CT，et al.Adjuvant paclitaxel and trastuzumab for node-negative，HER2-positive breast cancer［J］.N Engl J Med，2015，372(2)：134-141.
[15]VENKATESAN P.Trastuzumab emtansine for HER2-positive breast cancer［J］.Lancet Oncol，2016，17(12)：e528.
[16]VALTORTA E，MARTINO C，SARTORE-BIANCHI A，et al.Assessment of a HER2 scoring system for colorectal cancer：Results from a validation study［J］.Mod Pathol，2015，28(11)：1481-1491.
[17]江泽飞，邵志敏，徐兵河.人表皮生长因子受体2阳性乳腺癌临床诊疗专家共识2016［J］.中华医学杂志，2016，96(14)：1091-1096. JIANG ZF，SHAO ZM，XU BH.Consensus of clinical diagnosis and treatment of human epidermal growth factor receptor-2 positive breast cancer［J］.Chinese Medical Journal，2016，96(14)：1091-1096.
[18]HARBECK N，HUANG CS，HURVITZ S，et al.Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment(LUX-Breast 1)：An open-label，randomised，phase 3 trial［J］.Lancet Oncol，2016，17(3)：357-366.
[19]李娜妮，刘健，吴凡，等.拉帕替尼联合白蛋白结合型紫杉醇治疗曲妥珠单抗治疗失败的HER2阳性乳腺癌的临床观察［J］.中华内分泌外科杂志，2016，10(5)：369-373. LI NN，LIU J，WU F，et al.Clinical observation of lapatinib combined with albumin binding taxol in the treatment of HER2 positive breast cancer with trastuzumab failure［J］.Chinese Journal of Endocrinology and Surgery，2016，10(5)：369-373.
[20]李健斌，江泽飞.2019年CSCO BC指南更新要点解读［J］.中国肿瘤外科杂志，2019，11(03)：155-160. LI JB，JIANG ZF.Interpretation of key points of CSCO BC guidelines update in 2019［J］.Chinese Journal of Oncology and Surgery，2019，11(03)：155-160.

Memo

Memo:
陕西省科学技术研究发展计划项目（编号：2012SF2-13-01）；陕西省卫生与计划生育委员会资助项目（编号：WJ20156832）
Last Update: 2020-11-30